W M Drake|S J Howell|J P Monson|S M Shalet - JoVE Visualize

Showing results (11-20 of 499) with videos related to

Pageof 50

Sort By:

Clinical Endocrinology|November 26, 2015

Circadian variation in serum cortisol during hydrocortisone replacement is not attributable to changes in cortisol-binding globulin concentrationsT T Chung, K Gunganah, J P Monson, et al.

European Journal of Endocrinology|August 3, 2005

Markers of cell proliferation in a GH-producing adenoma of a patient treated with pegvisomantW M Drake, D M Berney, K Kovacs, et al.

Clinical Endocrinology|May 3, 2000

Pre-treatment IGF-I level is the major determinant of GH dosage in adult GH deficiencyR D Murray, S J Howell, C A Lissett, et al.

British Journal of Cancer|March 25, 2000

Fatigue, sexual function and mood following treatment for haematological malignancy: the impact of mild Leydig cell dysfunctionS J Howell, J A Radford, E M Smets, et al.

Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 20, 1999

Testicular function after cytotoxic chemotherapy: evidence of Leydig cell insufficiencyS J Howell, J A Radford, W D Ryder, et al.

Clinical Endocrinology|May 3, 2000

The impact of mild Leydig cell dysfunction following cytotoxic chemotherapy on bone mineral density (BMD) and body compositionS J Howell, J A Radford, J E Adams, et al.

European Journal of Endocrinology|September 2, 2004

Transitional care of GH deficiency: when to stop GH therapyM O Savage, W M Drake, P V Carroll, et al.

European Journal of Endocrinology|March 5, 2005

Consensus statement on the management of the GH-treated adolescent in the transition to adult careP E Clayton, R C Cuneo, A Juul, et al.

Clinical Endocrinology|October 9, 2001

Randomized placebo-controlled trial of testosterone replacement in men with mild Leydig cell insufficiency following cytotoxic chemotherapyS J Howell, J A Radford, J E Adams, et al.

Clinical Endocrinology|September 1, 1999

Dose titration and patient selection increases the efficacy of GH replacement in severely GH deficient adultsR D Murray, C J Skillicorn, S J Howell, et al.

Pageof 50

Showing results (11-20 of 499) with videos related to

Sort By:

Pageof 50

Clinical Endocrinology|November 26, 2015

Circadian variation in serum cortisol during hydrocortisone replacement is not attributable to changes in cortisol-binding globulin concentrationsT T Chung, K Gunganah, J P Monson, et al.

European Journal of Endocrinology|August 3, 2005

Markers of cell proliferation in a GH-producing adenoma of a patient treated with pegvisomantW M Drake, D M Berney, K Kovacs, et al.

Clinical Endocrinology|May 3, 2000

Pre-treatment IGF-I level is the major determinant of GH dosage in adult GH deficiencyR D Murray, S J Howell, C A Lissett, et al.

British Journal of Cancer|March 25, 2000

Fatigue, sexual function and mood following treatment for haematological malignancy: the impact of mild Leydig cell dysfunctionS J Howell, J A Radford, E M Smets, et al.

Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 20, 1999

Testicular function after cytotoxic chemotherapy: evidence of Leydig cell insufficiencyS J Howell, J A Radford, W D Ryder, et al.

Clinical Endocrinology|May 3, 2000

The impact of mild Leydig cell dysfunction following cytotoxic chemotherapy on bone mineral density (BMD) and body compositionS J Howell, J A Radford, J E Adams, et al.

European Journal of Endocrinology|September 2, 2004

Transitional care of GH deficiency: when to stop GH therapyM O Savage, W M Drake, P V Carroll, et al.

European Journal of Endocrinology|March 5, 2005

Consensus statement on the management of the GH-treated adolescent in the transition to adult careP E Clayton, R C Cuneo, A Juul, et al.

Clinical Endocrinology|October 9, 2001

Randomized placebo-controlled trial of testosterone replacement in men with mild Leydig cell insufficiency following cytotoxic chemotherapyS J Howell, J A Radford, J E Adams, et al.

Clinical Endocrinology|September 1, 1999

Dose titration and patient selection increases the efficacy of GH replacement in severely GH deficient adultsR D Murray, C J Skillicorn, S J Howell, et al.

Pageof 50